EKSO Ekso Bionics Holdings Inc

Ekso Bionics to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020

Ekso Bionics to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020

RICHMOND, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer of Ekso Bionics, will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference at 11:30 am ET / 8:30 am PT on Wednesday, September 16, 2020.

A live and archived webcast of the presentation will be available on the investor section of the company’s website at: .

About Ekso Bionics® 

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit:  or follow @EksoBionics on Twitter.

Media Contact:

Carrie Yamond Mas

917-371-2320

Investor Contact:

David Carey

212-867-1768

 

EN
09/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ekso Bionics Holdings Inc

 PRESS RELEASE

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successfully demonstrated initial proof-of-concept in ...

 PRESS RELEASE

Ekso Bionics Announces New Effective Date of Reverse Stock Split

Ekso Bionics Announces New Effective Date of Reverse Stock Split SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Ma...

 PRESS RELEASE

Ekso Bionics Announces Reverse Stock Split

Ekso Bionics Announces Reverse Stock Split SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company’s common stock will trade under a ne...

 PRESS RELEASE

Ekso Bionics Accepted into NVIDIA Connect Program

Ekso Bionics Accepted into NVIDIA Connect Program Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVI...

 PRESS RELEASE

Ekso Bionics Reports First Quarter 2025 Financial Results

Ekso Bionics Reports First Quarter 2025 Financial Results SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility (“NSM”) as its exclusive Ekso Indeg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch